Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Expenses (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Expenses for 6 consecutive years, with $67.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 20.42% to $67.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $318.1 million, a 16.83% decrease, with the full-year FY2025 number at $318.1 million, down 16.83% from a year prior.
  • Operating Expenses was $67.6 million for Q4 2025 at Relay Therapeutics, down from $80.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $194.4 million in Q2 2021 to a low of $43.4 million in Q1 2021.
  • A 5-year average of $88.4 million and a median of $85.6 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 601.41% in 2021, then crashed 59.79% in 2022.
  • Relay Therapeutics' Operating Expenses stood at $68.3 million in 2021, then rose by 7.05% to $73.1 million in 2022, then increased by 26.11% to $92.2 million in 2023, then fell by 7.83% to $85.0 million in 2024, then dropped by 20.42% to $67.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Operating Expenses are $67.6 million (Q4 2025), $80.4 million (Q3 2025), and $77.5 million (Q2 2025).